54 results about "Fluconazole" patented technology

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention relates to the technical field of medicines, in particular to application of tedizolid combined with fluconazole in preparation of antifungal drugs. The tedizolid and the fluconazole are combined for use, so that the antibacterial activity of the fluconazole on the candida albicans can be enhanced, a synergistic antifungal effect can be generated, and the drug resistance of the candida albicans on the fluconazole can be reversed.

The invention relates to the field of medicinal emulsifiable paste, in particular to compound fluconazole emulsifiable paste and a preparation method thereof. The compound fluconazole emulsifiable paste is prepared from the following components in parts by weight: 0.6 to 5 parts of fluconazole, 0.2 to 2 parts of neomycin sulfate, 0.1 to 0.2 part of triamcinolone acetonide, 5 to 15 parts of stearic acid, 10 to 25 parts of white vaseline, 2 to 8 parts of glyceryl monostearate, 0.5 to 3 parts of medicinal dimeticone, 1 to 5 parts of polysorbate-80, 0.1 to 0.3 part of sorbic acid, 0.1 to 1 part of vitamin E, 0.01 to 0.1 part of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 5 to 15 parts of glycerol and the balance of purified water, wherein the total amount is 100 parts. According to the application, the antioxidant property of the cream is improved by adding the vitamin E and the EDTA disodium, the vitamin E is used for directly scavenging free radicals, the EDTA disodium is used for eliminating an oxidation catalyst, and the quality guarantee period of the cream can be remarkably prolonged and the drug effect can be maintained by combining the vitamin E and the EDTA disodium.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The application provides an application of a compound HEX and / or a compound POM-HEX in medicine for preventing and / or treating fungal infection, and belongs to the technical field of medicine. In vitro experiments show that POM-HEX alone has inhibiting effects on candida and cryptococcus, and when combined with fluconazole, the antifungal activity can be significantly improved, and the drug-resistant strains can restore the sensitivity to fluconazole. The organ bacterial load experiment in mice in vivo proves that POM-HEX can stably exert the drug efficacy in the organism. In addition, the IC 50 value of the metabolic product HEX of POM-HEX for inhibiting the Eno1 enzyme activity of Candida albicans is 1 / 30 of the IC 50 of HEX for inhibiting the Eno1 enzyme activity of human. The application discloses that the HEX and / or the compound have strong antifungal activity and high selectivity for the target point Eno1, provides a new idea for antifungal treatment, the drug combination can reduce the drug dosage, reduce the toxic and side effects, and solves the problem of fungal drug resistance.

The present invention relates to methods and means for inhibiting or preventing the growth of fungal cells with at least one flavone selected from the group consisting of 5-methoxyflavone, 2′-methoxyflavone, 7-methoxyflavone, 3′,4′,5,7-tetrametoxyflavone, 3′,4′,5′,5,6,7-hexymethoxyflavone, 7,8-benzoflavone and 5,6-benzoflavone for inhibiting or preventing the growth of a fungal cell, wherein said flavone is used in combination with at least one further antimycotic compound selected from the group of azoles, both in an amount to exhibit a synergistic effect compared to the separate use of said flavone and said antimycotic compound.

The invention belongs to the technical field of lithium-sulfur all-solid-state battery materials, and discloses a preparation method of a pre-lithiated lithium-sulfur battery positive electrode. Fluconazole and lithium are selected for coordination, and a surfactant is combined with the functionalized carbon nanotubes. And melting sublimated sulfur, and pulping with a binder to prepare a pre-lithiated lithium-sulfur positive electrode. The pole piece is assembled into the solid-state lithium-sulfur battery, so that electrons / ions can be permanently and efficiently transmitted in the battery, the utilization rate of active substances is further improved, and the solid-state lithium-sulfur battery with long service life and stable circulation is realized.

The invention belongs to the technical field of pesticides, and particularly relates to a pesticide fertilizer for preventing and treating corn stem rot. The invention relates to a pesticide active component. The pesticide active component is prepared by compounding ifen trifluconazole and pydiflumetofen according to a mass ratio of (1-9): (9-1). According to the invention, the ifen trifluconazole and the pydiflumetofen are compounded into a pesticide active component with a bactericidal effect, so that the prevention and treatment effect on the corn stem rot can be improved, the drug resistance risk of the pesticide can be reduced, and a support can be provided for developing a novel efficient compound bactericide for preventing and treating the corn stem rot. In addition, the functional pesticide-fertilizer granules are formed by combining pesticide active ingredients with the fertilizer, have the pesticide effect and the fertilizer effect, have the pesticide effect and the fertilizer effect through one-time application, and have good application prospects.

The invention belongs to the technical field of biological medicines, and in particular relates to an application of hyssopus rigidus var. Cupidus essential oil in preparation of an antibiotic antibacterial sensitizer and / or preparation of an antibiotic combined medicine, and further relates to an application of the hyssopus rigidus var. Cupidus essential oil in preparation of the antibiotic antibacterial sensitizer and / or the antibiotic combined medicine. It is found that the hyssop officinalis essential oil can enhance the antibacterial sensitivity of various antibiotics including fluconazole and amphotericin B, the hyssop officinalis essential oil and the antibiotics are combined for use, the synergistic antibacterial activity is achieved, and the better antibacterial effect is achieved while the dosage of the antibiotics is reduced; important technical support is provided for improving the current situation of drug resistance of fungi.

The application provides a long-acting external use efinaconazole composition, a preparation method and application, and belongs to the technical field of pharmaceutical compositions.The long-acting external use efinaconazole composition comprises the following components in percentage by weight: efinaconazole 0.5-3%, a film forming agent 3-7%, a gel agent 2-3%, a plasticizer 3-7%, a cosolvent 0.78-1.56% and a solvent in a residual amount.The application forms a eutectic mixture of efinaconazole and lactic acid, improves the solubility and permeability of the active ingredient, dissolves in the solvent of an ethanol system, and adds the film forming agent and the plasticizer, so that a drug depot is formed on the surface of the skin through the film forming principle, the drug is released slowly, the clinical compliance is improved, the frequency of drug administration is reduced, the bioavailability of the drug in the stratum corneum is increased, the effectiveness and safety of the drug can be improved, the basic theory of pharmacoeconomics is met, and the clinical value of the product is improved.

The invention relates to the technical field of drug analysis and detection, and provides a method for detecting 1, 2, 4-triazole in fluconazole sodium chloride injection, which adopts high performance liquid chromatography. The specific conditions of the high performance liquid chromatography are as follows: a solvent is a water-acetonitrile mixed solution with the volume ratio of 95: 5; the mobile phase comprises a mobile phase A and a mobile phase B, the mobile phase A is water, and the mobile phase B is acetonitrile; the flow velocity is 1.0 mL / min; octadecylsilane chemically bonded silica is used as a filling agent of a chromatographic column; the column temperature is 30 DEG C; the sample injection volume is 100 microliters; performing gradient elution; and the detection wavelength is 195 nm. The method has the advantages that the content of 1, 2, 4-triazole in the fluconazole sodium chloride injection can be quantitatively and accurately determined without derivation reaction, the unification of operation convenience and detection accuracy is realized, and reliable technical support is provided for quality control of the fluconazole sodium chloride injection.

The invention relates to a candida auricula B9J08001173 gene overexpression strain, a preparation method thereof and application of the candida auricula B9J08001173 gene overexpression strain in drug resistance research. The Candida auris B9J08001173 gene overexpression strain is preserved in the China General Microbiological Culture Collection Center on February 19, 2025, and the preservation number of the Candida auris B9J08001173 gene overexpression strain is CGMCC (China General Microbiological Culture Collection Center) NO. 33592. The Candida auricula B9J08001173 gene overexpression strain CF1 (OE1173) is constructed for the first time at home and abroad, is an effective model for researching the function of the B9J08001173 gene and the action mechanism of the B9J08001173 gene in the drug resistance of the Candida auricula, can be used for researching the mechanism related to the drug resistance of fluconazole, and has great significance in research and development of related drugs and clinical research and medication guidance.

The invention discloses skin mucosa maintenance liquid capable of killing fungi and HPV (human papillomavirus) as well as a preparation method and application of the skin mucosa maintenance liquid, and belongs to the technical field of sterilization and virus removal. The skin mucosa maintenance liquid is prepared from octanol ether, benzalkonium bromide, phenoxyethanol, yermate, parachlorometaxylenol, taetinic acid, chitosan, keratinase, fluconazole, glycerol, borneol, menthol, absolute ethyl alcohol and tween-40. Wherein the skin mucosa maintenance liquid has an effect of regulating apoptosis induction on abnormal cells and an effect on vaginal flora, and has an obvious inhibition effect on cervicitis and colpitis mycotica, namely an anti-inflammatory effect; meanwhile, apoptosis of cells containing HPV16 and HPV18 genes can be induced, shedding of abnormal cells is promoted, diseased cells are killed, and vaginal tissues with pathological changes are removed.

The application belongs to the field of pharmaceutical preparations, and particularly relates to a fluconazole capsule and a preparation method thereof. The fluconazole capsule comprises a hollow capsule and a filling in the hollow capsule, and the filling is a fluconazole composition. The fluconazole composition comprises the following components by weight per 1000 capsules: 50g of fluconazole, 10-20g of spirulina extract, 5-15g of micronized silica gel, 0.1-1g of sodium alginate and 1-10g of naked flower purple perilla extract. The fluconazole capsule composition of the application adds the spirulina extract and the naked flower purple perilla extract in the fluconazole medicine, and adds the micronized silica gel and the sodium alginate, so that the flowability of the prepared composition is greatly improved, the medicine is uniformly dispersed, and the fluconazole capsule is beneficial to be divided. The prepared fluconazole capsule is uniform in quality, and the stability is greatly improved, so that the fluconazole capsule provides a guarantee for clinical use.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The invention discloses fluconazole ear drops and a preparation method of the fluconazole ear drops, and belongs to the technical field of ear drop preparations. The composition comprises the following components in percentage by mass: 0.6%-2.0% of fluconazole, 8%-20% of propylene glycol and / or diethylene glycol monoethyl ether, 20%-32% of glycerol or caprylic / capric polyethylene glycol glyceride, 0.1%-1% of hydroxypropyl methylcellulose, 0.05%-0.2% of anhydrous disodium hydrogen phosphate and the balance of anhydrous citric acid and water. By improving the prescription of the fluconazole ear drops, the solubility of the fluconazole is increased, the content of the fluconazole in the prepared fluconazole ear drops reaches 2%, the fluconazole ear drops are good in stability, and compared with the prior art, the fluconazole ear drops have a better treatment effect on ear fungal infection.

The invention discloses an application of PBT2 in preparation of an anti-candida albicans biofilm drug. The invention provides the whole process that the PBT2 can inhibit the formation of a candida albicans biofilm, and the PBT2 can be combined with fluconazole to play a synergistic effect. The PBT2 reduces the contents of Zn < 2 + >, Cu < 2 + > and Fe < 2 + > in the candida albicans, seriously interferes the steady state of metal ions in candida albicans cells, further affects the normal physiological functions of the candida albicans and inhibits the formation of a candida albicans biological membrane. According to the invention, the in-vivo antibacterial effect of the PBT2 is preliminarily verified in a greater wax moth larva model. The invention provides a new strategy for eliminating Candida albicans biofilm infection, and based on the confirmed safety of PBT2, the transformation of antifungal application of PBT2 can be quickly promoted.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

The present invention relates to a composition for oral use including a co-formed product of efinaconazole and polyethylene glycol and a pharmaceutically acceptable additive. The composition of the present invention has high stability and bioavailability and is thus very effective when administered.

The application discloses a long-chain non-coding RNA of Candida albicans for epigenetically regulating fluconazole resistance and application thereof, belongs to the technical field of biological medicines, and relates to antifungal medicines. The long-chain non-coding RNA for epigenetically regulating fluconazole resistance comprises three nucleotide sequences shown in SEQ ID NO. 1-3. The application further provides application of Momordica charantia protein MAP30 in inhibiting expression of the long-chain non-coding RNA of the Candida albicans genome. The application provides nucleotide sequencing of the long-chain non-coding RNA of the Candida albicans genome for epigenetically regulating fluconazole resistance, open reading frame (ORF) alignment, positioning of the lncRNA on a chromosome, inhibition of lncRNA expression by using the Momordica charantia protein MAP30, and realization of reversing fluconazole resistance, which provides a theoretical basis for revealing the Candida albicans resistance mechanism, developing new antifungal medicines and treatment strategies.

The application discloses an antifungal azole derivative, a synthesis method and application thereof, and has a general formula shown in formula (I). The azole derivative is synthesized by recombination of fluconazole and ketoconazole structural units, and the application of the azole derivative provided by the application is the application in preparation of antifungal drugs. The azole derivative synthesized by the application is superior to fluconazole (FLC) in inhibiting effect on Candida albicans, and the MIC 50 value can be as low as 0.0218 μg / mL, thereby providing a new direction for research and preparation of an antifungal drug for Candida albicans.

The present invention discloses a method for enhancing the anti-Candida albicans biofilm activity of azole drugs by utilizing a zinc ion chelator. Through the combined action of the zinc ion chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) and fluconazole, the activity of the Candida albicans biofilm can be reduced, the early adhesion process, the mid-term yeast to hyphae conversion process, and the late maturation process of the Candida albicans biofilm formation can be inhibited, the Candida albicans biofilm structure can be destroyed, and the high drug resistance of the Candida albicans biofilm to fluconazole can be reversed, and its pathogenicity can be reduced. The method is expected to solve the problems of high drug resistance and persistent infection caused by the formation of the Candida albicans biofilm, and provide a direction for the treatment of clinical fungal infections and drug research and development.

The present application relates to a kind of secreting voriconazole monoclonal antibody hybridoma cell strain and its application, belong to immune detection technical field.The present application is prepared by screening and obtains a kind of hybridoma cell strain capable of secreting voriconazole monoclonal antibody, the monoclonal antibody secreted by the hybridoma cell strain of the present application has good sensitivity and specificity to voriconazole, specifically, the IC 50 Value of the monoclonal antibody of the present application to voriconazole is 10 ng / mL, and the cross-reactivity of voriconazole structural analog (fluconazole, posaconazole, albaconazole) is less than 10%, so that low concentration of voriconazole can be accurately detected.

The invention relates to the technical field of foreign matter detection, and particularly discloses a fluconazole sodium chloride injection filling foreign matter detection device which comprises a foreign matter detection production line used for fluconazole sodium chloride injection filling, and the foreign matter detection production line is provided with a first detection station, a second detection station and an empty bottle conveying line. The first detection station and the second detection station are used for detecting empty bottles on the empty bottle conveying line, and both the first detection station and the second detection station are used for image detection; the first detection station detects the bottle bottom of an empty bottle to obtain a bottle bottom image, the second detection station comprises a left detection link and a right detection link which are used for obtaining a side body image, a side upper body image and a side lower body image of the empty bottle, and the second detection station obtains mirror images of the side body image, the side upper body image and the side lower body image of the empty bottle based on an empty bottle rotating assembly; and performing mirror image combination analysis on the side body image, the side upper body image and the side lower body image of the left detection link and the side body image, the side upper body image and the side lower body image of the right detection link.

The application discloses fluconazole ear drops and a preparation method thereof, and belongs to the technical field of ear drop preparations. The fluconazole ear drops contain the following components in percentage by mass: 0.6%-2.0% of fluconazole, 8%-20% of propylene glycol and / or diethylene glycol monoethyl ether, 20%-32% of glycerol or capryl capric acid polyethylene glycol glycerol ester, 0.1%-1% of hydroxypropyl methyl cellulose, 0.05%-0.2% of anhydrous disodium hydrogen phosphate, and water in a residual amount. The solubility of fluconazole is increased through improvement of the prescription of the fluconazole ear drops, the content of fluconazole in the prepared fluconazole ear drops reaches 2%, and the fluconazole ear drops have good stability. Compared with the prior art, the fluconazole ear drops have a better treatment effect on ear fungal infections.

The invention relates to a Candida auricula B9J08001173 gene knockout strain, a preparation method thereof and an effect of the Candida auricula B9J08001173 gene knockout strain in drug resistance research. The Candida auris B9J08001173 gene knockout strain is preserved in the China General Microbiological Culture Collection Center on February 19, 2025, and the preservation number of the Candida auris B9J08001173 gene knockout strain is CGMCC (China General Microbiological Culture Collection Center) NO.33591. The Candida auris B9J08001173 gene knockout strain disclosed by the invention is a Candida The Candida auricula B9J08001173 gene knockout strain CF1 (KO1173) is constructed for the first time at home and abroad, is an effective model for researching the function of the B9J08001173 gene and the action mechanism of the B9J08001173 gene in the drug resistance of the Candida auricula, can be used for researching the mechanism related to the drug resistance of fluconazole, and has great significance in research and development of related drugs and clinical research and medication guidance.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

Disclosed in the present invention are antifungal compounds, a preparation method therefor, and the use thereof. The compounds have the following general formula I, wherein L represents a linking moiety, referring to a small molecule fragment, and Ar represents a heterocyclic ring or a substituted heterocyclic ring. The series of compounds of the present invention can better bind to an enzyme target by means of various interaction forces, thereby exhibiting good activity; and the compounds exhibit excellent activity in both in vitro experiments and animal experiments, the activity of most of the compounds against Candida albicans being better than that of fluconazole. In addition, the series of compounds have anti-inflammatory effects while eliminating fungal infections; and compared with voriconazole, the series of compounds of the present invention can remarkably down-regulate the expression of an inflammatory factor interleukin 6.

The invention discloses a verification method and application of an ADH2 gene in systemic Candida albicans infection treatment, and belongs to the technical field of microbial medicine and anti-infection treatment. The verification method comprises the following steps: constructing an ADH2 single allele knockout strain and an ADH2 double allele knockout strain by taking wild type candida albicans SC5314 as a starting strain, and evaluating the effectiveness of an ADH2 target spot through body and appearance verification, in-vitro metabolism verification, in-vitro drug sensitivity verification and immunosuppression mouse in-vivo pathogenicity and curative effect verification. In the application aspect, the medicine for treating systemic Candida albicans infection is prepared by regulating and controlling the function of the ADH2 gene in the Candida albicans, the abnormal metabolism of a biological membrane caused by function imbalance of the ADH2 can be corrected, and the sensitivity of the Candida albicans to fluconazole is enhanced or the toxicity of the Candida albicans is reduced. The invention provides a new intervention way for the drug resistance problem of the antifungal drug, and provides technical support for research and development of the antifungal drug.